肺がんと結核を併発した患者の生存予測のための炎症栄養バイオマーカーモデル
Hongqi Zhou1, Zihao Zhao2, Jinhai Wang3
1Oncology Department, Guiyang Public Health Treatment Center, Guiyang, China.
Frontiers in molecular biosciences
|August 20, 2025
まとめ
この研究は,炎症栄養マーカーを用いた肺がんと結核患者の新しい予後モデルを開発した. このモデルは生存率を正確に予測し 標的を絞った介入のために 高いリスクのある個人を特定します
科学分野:
- 腫瘍学
- 肺科
- バイオマーカー
- 予測モデリング
背景:
- 肺がんと結核 (TB) の併発症は 独特の予後問題をもたらします
- 現存する予後モデルでは,この特定の患者群に適切に対応できません.
- 炎症と栄養のマーカーは様々な病気の結果を予測する可能性を 示しています
研究 の 目的:
- 併発性肺がんと結核患者の多次元予後モデルを開発し,検証する.
- この集団における8つの炎症栄養バイオマーカーの予後値を評価する.
- リスクの階層化のためのツールを提供し,潜在的な介入を導く.
主な方法:
- 肺がんと結核を患った100人の患者さんによる遡及研究.
- 8つの炎症栄養マーカー (NLR,PLR,SII,LMR,PNI,HALP,HRR,ALB/GLB) を予測剤として使用した.
- 特徴の選択のためにLASSO回帰と生存分析のためのCox比例リスクモデルを使用した.
- ROC曲線,C指数,ブートストラップ再採取による校正グラフを用いてモデルの性能を評価した.
主要な成果:
- 最終的なモデルには糖尿病,ECOG PS,NLR,PNI,HRR,RDWが含まれていた.
- ECOG PSは独立した予後因子 (HR=1. 76,p=0. 04) として特定された.
- ノモグラムは良好な性能 (C指数=0. 71) と優れた校正を示した.
- 高リスクサブグループ (ECOG PS ≥2,NLR>8) は,ほぼゼロの5年生存率を示した.
- ECOGのPSとNLR (p=0. 032) の間に有意な相互作用が認められた.
結論:
- これは肺がんと結核患者の 炎症と栄養のマーカーを組み合わせた 最初の検証済みの予後モデルです
- このモデルは,個々のリスクの階層化のための定量的なツールとして機能します.
- 発見は,高リスク患者のための栄養介入の検討を支持します.
さらに関連する動画
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
18.9K
07:42Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1
Published on: February 28, 2025
568
関連する概念動画
Pulmonary Tuberculosis IV
196
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
196
Pulmonary Tuberculosis III
438
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
438
Pulmonary Tuberculosis I
321
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
321
Pulmonary Tuberculosis II
339
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
339
Pulmonary Tuberculosis V
236
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
236
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
407
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
407
